Imad Ajjawi
Corporate Officer/Principal bei ABSCI CORPORATION
Profil
Imad Ajjawi is the founder of Denovium, Inc. He currently works as the Vice President-Business Development at Absci Corp.
His education includes an MBA from the University of California San Diego and a doctorate from the University of Nevada.
Aktive Positionen von Imad Ajjawi
| Unternehmen | Position | Beginn |
|---|---|---|
| ABSCI CORPORATION | Corporate Officer/Principal | 01.01.2021 |
Denovium, Inc.
 Denovium, Inc. Packaged SoftwareTechnology Services Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million. | Gründer | - |
Ausbildung von Imad Ajjawi
| University of California San Diego | Masters Business Admin |
| University of Nevada | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ABSCI CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Denovium, Inc.
Denovium, Inc. Packaged SoftwareTechnology Services Part of Absci Corp., Denovium, Inc. is an American artificial intelligence company that pioneers novel AI methods to accelerate innovation in biology. Denovium is building an artificial intelligence engine (Denovium EngineTM) capable of interpreting disparate biological data types to answer biology's toughest questions. The company partners with leading biotech and pharma companies in specific areas of focus, including gene discovery, protein engineering, and genomic medicine. The company was founded by Toby H. Richardson, Ariel Schwartz, Imad Ajjawi, and Gregory Hannum, with Toby H. Richardson serving as the CEO since incorporation. Denovium was acquired by Absci Corp. on January 12, 2021 for $4 million. | Technology Services |
